FDA approves Pfizer’s eczema ointment
The U.S. Food and Drug Administration said on Wednesday it had approved Pfizer Inc’s Eucrisa ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older.
-
Costs vary for moisturizers used to ease eczema in babies
-
Research links eczema and hay fever to early antibiotic use
-
For kids with eczema, ‘soak and smear’
Atopic dermatitis is the most common of the many types of eczema, typically beginning in childhood and possibly lasting through adulthood.
Pfizer bought Anacor Pharmaceuticals in a $5.2 billion deal earlier this year to add the ointment to its portfolio.